On Feb.13, Momenta Pharmaceuticals (NASDAQ:MNTA) released fourth-quarter earnings for the period ended Dec. 31.

  • The company is moving towards a U.S. launch of M-Enoxaparin.
  • For 2007, management plans to advance the commercial readiness of the M-Enoxaparin program, complete the phase 1 clinical studies for M118 intravenous injection, and commence the phase 2 clinical program for M118 in the second half of the year.
  • In the longer term, the company plans to define a broader research strategy for building its drug pipeline.

(Figures in thousands, except per-share data)

Income Statement Highlights

Q4 2006

Q4 2005






Net Profit








Diluted Shares




Get back to basics with a look at the income statement.

Margin Checkup

Q4 2006

Q4 2005


Gross Margin

No Data

No Data

No Data

Operating Margin




Net Margin




*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights


Q4 2006

Q4 2005


Cash + ST Invest.




Accounts Rec.

No Data

No Data

No Data


No Data

No Data

No Data

Momenta didn't provide any information on liabilities.

Learn the ways of the balance sheet.

Cash Flow Highlights
Momenta didn't chip in any cash flow info, either. For shame!

Find out why Fools always follow the money.

Related Companies:

  • Human Genome Sciences (NASDAQ:HGSI)
  • Flamel (NASDAQ:FLML)
  • Teva Pharmaceuticals (NASDAQ:TEVA)
  • Nabi Biopharmaceuticals (NASDAQ:NABI)

Related Foolishness:

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.

Momenta Pharmaceuticals is a Motley Fool Rule Breakers recommendation, while Flamel is a Motley Fool Hidden Gems selection. Try any of our Foolish newsletters free for 30 days.

This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below. The Fool has a disclosure policy.